Annual International Primary CNS Lymphoma Collaborative Group Meeting

年度国际原发性中枢神经系统淋巴瘤合作小组会议

• 批准号: 9261060
• 负责人: Tracy T Batchelor
• 金额: $ 0.5万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2017-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9261060
• 关键词: Age; American Society of Hematology; California; Central Nervous System Lymphoma; Clinical Trials; Clinical Trials Design; Collaborations; Comorbidity; Country; Cranial Irradiation; Diagnosis; Diagnostic; Discipline; Elderly; Extranodal; Group Meetings; High Dose Chemotherapy; International; Lymphoma; Malignant neoplasm of brain; Medical; Nervous system structure; Non-Hodgkin' s Lymphoma; Patient Participation; Patients; Peer Review; Population; Publishing; Research; Review Literature; Risk; Specialist; Therapeutic; Treatment Protocols; Variant; aggressive therapy; meetings; neurotoxicity; older patient; symposium

Project Summary Primary central nervous system lymphoma (PCNSL) is an extranodal variant of non-Hodgkin lymphoma (NHL) that is confined to the nervous system. The diagnostic and therapeutic approaches to PCNSL are different from those that are applied to other forms of NHL or to other brain cancers. The International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) consists of specialists from multiple countries and disciplines dedicated to the study of PCNSL. The IPCG holds an annual scientific conference at the American Society of Hematology meeting in which various research topics related to PCNSL are discussed. An international expert on the topic under discussion is selected each year by an executive committee to chair the scientific conference. These meetings have led to multiple collaborative projects that have positively impacted the field and that have been published in the peer-reviewed literature. The annual IPCG meeting is a critical forum for generating new ideas and approaches to this unique form of brain cancer and lymphoma. The 2016 conference topic is Management of Elderly Patients with PCNSL. The median age at diagnosis of PCNSL is 65 but many clinical trials exclude elderly patients from participation. Co-morbidities and increased risk of neurotoxicity limit application of aggressive therapies like high-dose chemotherapy and whole brain radiation in this population. Clinical trials specifically for elderly PCNSL are limited and this represents an unmet medical need. A conference focused on this problem is of high priority for the IPCG.

项目摘要 原发性中枢神经系统淋巴瘤（PCNSL）是非霍奇金淋巴瘤（NHL）的一种淋巴结变异型 仅限于神经系统。PCNSL的诊断和治疗方法不同 与其他形式的NHL或其他脑癌不同。国际小学中心 神经系统淋巴瘤协作组（IPCG）由来自多个国家的专家组成， 致力于PCNSL研究的学科。IPCG每年在美国举行一次科学会议。 血液学学会会议，其中讨论了与PCNSL相关的各种研究主题。一个 每年由一个执行委员会选出一名国际专家， 科学会议。这些会议促成了多个合作项目， 该领域和已发表在同行评审的文献。年度IPCG会议是一个关键的 论坛产生新的想法和方法，以这种独特的形式脑癌和淋巴瘤。2016年 会议主题是PCNSL老年患者的管理。诊断PCNSL时的中位年龄为 65但许多临床试验排除老年患者参与。合并症和风险增加 神经毒性限制了高剂量化疗和全脑放疗等积极治疗的应用， 这个人口。专门针对老年PCNSL的临床试验有限，这代表了未满足的医疗要求。 需要的IPCG高度重视召开一次重点讨论这一问题的会议。